Well, I topped up yesterday, and will again today. I think they...

Well, I topped up yesterday, and will again today. I think they have done well, and further details will be provided in good time, when things are signed. It is basically MOU at present, in MO.


TIS - TISSUE THERAPIES LIMITED

RBS Australia rates TIS as Buy (1) - Target $0.87 (was $0.95). AGM commentary indicated Tissue Therapies has entered an agreement to to launch VitroGro in Europe, which is a positive in the view of RBS. Also positive was impressive results from a clinical trial.
To reflect the update RBS has adjusted its model, the result being a modest cut in price target. Buy rating is retained.
Target price is $0.87 Current Price is $0.47 Difference: $0.4 If TIS meets the RBS Australia target it will return approximately 85% (excluding dividends, fees and charges).
The company's fiscal year ends in June. RBS Australia forecasts a full year FY12 dividend of 0.00 cents and EPS of minus 5.00 cents .
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 9.40.
Market Sentiment: 1.0